Interestingly, TBK1-loss did not slow down tumour growth in immunodeficient mice; however, targeting TBK1 pharmacologically promoted a more immunostimulatory effect in the TME because it increased the infiltration of CD8 T cells and M1 macrophage into tumours [103]. This evidence concerns the gene CD8A and neoplasm.